iShares Biotechnology ETF (IBB) AIQ Analysis
iShares Biotechnology ETF AIQ Score is 53/100 for investment merit, while Smart Score is 5/10 for peer-relative ranking, with Sharpe 1.53.
Last updated: Jul 26, 2026, 12:00 AM UTC
AIQ Brief
iShares Biotechnology ETF is currently in a mixed setup with AIQ 53/100 and Smart 5/10 (neutral relative) at $188.33. Risk is moderate. Read this as a prioritization signal, then confirm entry quality and sizing with your own risk plan.
Risk is the strongest contributor at 62/100, while Momentum is the binding constraint at 47/100. With a 15-point spread, the profile is reasonably balanced without a single dominant weakness.
IBB ranks 4/4 in this peer set (53 vs peer average 60.0). On risk-adjusted efficiency, Sharpe is above peer average (1.53 vs 0.96). This helps distinguish true relative leadership from broad sector drift.
Action now: this is a neutral/selective setup. Improve entry quality by waiting for momentum acceleration or a better risk profile before adding. Keep sizing moderate until factors align.
Sharpe is 1.53, indicating strong risk-adjusted return for this snapshot.
| AIQ Component | Score | Signal Read |
|---|---|---|
| Momentum | 47 | Mixed trend quality with uneven follow-through. |
| Value | 51 | Valuation appears close to fair value. |
| Quality | 55 | Quality profile is average for this universe. |
| Risk | 62 | Risk profile is moderate and manageable. |
| Sentiment | — | Sentiment signal is currently unavailable. |
Current AIQ Read
IBB currently screens as neutral. Wait for confirmation from trend quality and risk conditions before increasing exposure.
Loading IBB analysis...